Početna stranicaCVAC • NASDAQ
add
CureVac BV
2,80 $
Poslije radnog vremena:(0,00 %)0,00
2,80 $
Zatvoreno: 18. lis, 19:00:00 GMT -4 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
2,82 $
Dnevni raspon
2,80 $ - 2,86 $
Godišnji raspon
2,22 $ - 6,28 $
Tržišna kapitalizacija
628,08 mil. USD
Prosječna količina
421,98 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (EUR) | lip 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 14,44 mil. | 90,47 % |
Operativni troškovi | 44,97 mil. | −16,67 % |
Neto dohodak | −72,54 mil. | −7,61 % |
Neto profitabilnost | −502,51 | 43,51 % |
Zarada po dionici | −0,32 | −6,67 % |
EBITDA | −66,13 mil. | 0,71 % |
Efektivna porezna stopa | −1,83 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (EUR) | lip 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 202,52 mil. | −62,35 % |
Ukupna imovina | 556,84 mil. | −38,09 % |
Ukupne obveze | 180,30 mil. | −28,00 % |
Ukupni kapital | 376,53 mil. | — |
Dionice u optjecaju | 224,31 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,68 | — |
Povrat imovine | −28,56 % | — |
Povrat kapitala | −39,45 % | — |
Tok novca
Neto promjena novca
| (EUR) | lip 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −72,54 mil. | −7,61 % |
Gotovina od poslovanja | −89,11 mil. | −38,99 % |
Gotovina iz ulaganja | −7,49 mil. | 47,30 % |
Gotovina iz financiranja | −1,22 mil. | −1,67 % |
Neto promjena novca | −97,64 mil. | −22,67 % |
Slobodan tok novca | −74,99 mil. | −514,20 % |
Više
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Glavni izvršni direktor
Osnovano
2000
Web-lokacija
Zaposlenici
1.086
